Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/30/2003CA2144416C Method and composition for the treatment of hair loss
12/30/2003CA2140927C Platelet aggregation inhibitors
12/30/2003CA2132976C Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
12/30/2003CA2102241C Use of macrolide compounds for eye diseases
12/30/2003CA2099970C Composition for curing sjoegren syndrome disease
12/30/2003CA2096537C Method of administering dipalmitoylphosphatidylcholine dispersions
12/30/2003CA2091304C Substituted imidazole derivatives
12/30/2003CA2080555C Bis(phenyl)ethane derivatives
12/30/2003CA2076063C Sulfated glycosaminoglycanoid derivatives
12/30/2003CA2052884C Angiotensin 11 antagonists in the treatment of hyperuricemia
12/30/2003CA2051399C Therapeutically useful 2-aminotetralin derivatives
12/30/2003CA2040086C Novel 2,9-disubstituted-4h-pyrido[1,2-a]pyrimidin-4-ones
12/30/2003CA2001765C Chelants possessing ortho ligating functionality and complexes thereof
12/29/2003WO2004002469A1 Isoflavone concentrate and method for production thereof
12/29/2003CA2448513A1 Isoflavone concentrates, as well as methods for their production
12/29/2003CA2433983A1 Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses
12/28/2003CA2433237A1 Use of chloroquine, hydroxy chloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards hiv sensitive strains and towards hiv strains which are resistant to both nucleosidic and nonnucleosidic reverse transcriptase inhibitors and to proteases inhibitors
12/26/2003CA2391691A1 Modified release pharmaceutical composition containing bupropion hci as active substance
12/25/2003WO2003106461A2 Pseudopolymorphic forms of a hiv protease inhibitor
12/25/2003WO2003106424A1 Process for the manufacture of quinoline derivatives
12/25/2003WO2003105846A1 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
12/25/2003WO2003105611A2 Beverages containing plant sterols
12/25/2003WO2003105605A2 Use of pullulan as a slowly digested carbohydrate
12/25/2003US20030237101 Stem cell factor; modulation of gene expression
12/25/2003US20030236435 Synthesis of 2-alkylcysteine via substituted thiazoline ester
12/25/2003US20030236434 Condensing cysteine with cabocyclic nitriles to form 2-arylthiazoline-4-carboxylic acid, then amidation, alkylation, hydrolyzing and optionally purifying to form 2-methylcysteine
12/25/2003US20030236426 Synthesis of benzimidate from benzoic acid
12/25/2003US20030236420 Pharmaceuticals
12/25/2003US20030236417 A 4,5-Dihydro-2-(2,4-dihydroxyphenyl)-thiazole-4(S)-carboxylic acid or ester derivatives, use as iron metabolic chelators in therapeutic applications; demetallization
12/25/2003US20030236415 Etherifying mucochloric or mucobromic acid with an alcohol, alkylation, hydrogenation, dehydrochlorination or dehydrobromination, decyclization by reductive amination and carboxylation; 3-Aminomethyl-5-methyl-hexanoic acid
12/25/2003US20030236412 Cyclic AMP-specific phosphodiesterase inhibitors
12/25/2003US20030236411 Antisecretory agents for treating a peptic ulcer
12/25/2003US20030236408 Estrogenic compounds as anti-mitotic agents
12/25/2003US20030236406 Amination forming a benzylammonium methyl phenoxy 5-tetrahydrobenzothiepine; apical sodium co- dependent bile acid transporter inhibitors, anticholesterol agents
12/25/2003US20030236405 7-hetero-bicyclo[2.2.1]-heptanes
12/25/2003US20030236404 Synthesis of 2-alkylcysteine via phase transfer catalysis
12/25/2003US20030236402 A caspase-3 enzyme inhibitors, 3-(3-alkyl-amino-2-oxo-1,2-dihydro-1-pyrazinyl-alkanoylamino) -4-oxopentanoic acid; treating cardiac or cerebral ischemia or reperfusion injury, diabetes, AIDS
12/25/2003US20030236391 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy
12/25/2003US20030236309 Novel formate salt of O-desmethyl-venlafaxine
12/25/2003US20030236308 Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
12/25/2003US20030236307 Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
12/25/2003US20030236306 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
12/25/2003US20030236304 Fluorobenzamides and uses thereof
12/25/2003US20030236303 Therapeutic compositions and methods of use
12/25/2003US20030236302 Plant extracts; central nervous system disorders
12/25/2003US20030236301 Liposomal delivery of vitamin E based compounds
12/25/2003US20030236300 Releasing confined proteins; administering synergistic mixture of curcumin and enzyme inhibitor
12/25/2003US20030236299 Promoting biosynthsis of collagen; collagenase inhibitors; topical applying to skins
12/25/2003US20030236298 Antiinflammatory agents; antihistamines; skin disorders
12/25/2003US20030236297 Immunosuppressants; autoimmune diseases
12/25/2003US20030236294 Anticancer agents
12/25/2003US20030236293 Synergistic mixtures
12/25/2003US20030236292 Novel glucagon antagonists
12/25/2003US20030236291 Antitumor agents
12/25/2003US20030236289 Antiinflammatory agents; analgesics; antipyretics; cyclooxygenase inhibitor
12/25/2003US20030236288 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
12/25/2003US20030236286 Central nervous system disorders; cardiovascular disorders; antiischemic agents; psychological disorders
12/25/2003US20030236285 Stabilized pharmaceutical compositions containing benzimidazole compounds
12/25/2003US20030236284 Topical applying
12/25/2003US20030236281 Quinoline derivatives(2)
12/25/2003US20030236280 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
12/25/2003US20030236279 Central nervous system disorders; psychological disorders
12/25/2003US20030236278 Serotonine receptors antagonist; central nervous system disorders
12/25/2003US20030236275 Using desloratadine
12/25/2003US20030236273 Aryl substituted pyrimidines and the use thereof
12/25/2003US20030236272 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
12/25/2003US20030236271 Antitumor agents; enzyme inhibitors
12/25/2003US20030236270 Central nervous system disorders
12/25/2003US20030236269 Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
12/25/2003US20030236268 Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
12/25/2003US20030236267 Benzimidazole derivatives
12/25/2003US20030236265 Bactericides; autoimmune disease; antiinflammatory agents; administering a synergistic mixture of rifamycin and another antibiotic
12/25/2003US20030236264 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
12/25/2003US20030236263 Chemical compounds
12/25/2003US20030236262 Dietetics; antidiabetic agents; sexual disorders
12/25/2003US20030236260 Antiarthritic agents; autoimmune diseases; anticholesterol agents; cardiovascular disorders; antiinflammatory agents
12/25/2003US20030236258 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
12/25/2003US20030236255 Immunosuppressive effects of pteridine derivatives
12/25/2003US20030236253 Gabapentin; antiepileptic agents, analgesics
12/25/2003US20030236252 Brain disorders, cardiovascular disorders, strokes, Parkinson's disease
12/25/2003US20030236251 Hepatitis virus viricides
12/25/2003US20030236250 Antidepressants, anxiolytic agents, analgesics, antiinflammatory agents, reduce concentration of tachykinins
12/25/2003US20030236249 Prevent binding to chemokines
12/25/2003US20030236248 Kappa agonist compounds and pharmaceutical formulations thereof
12/25/2003US20030236247 Anticancer agents; autoimmune diseases; antiinflammatory agents
12/25/2003US20030236246 Administering staurosporine
12/25/2003US20030236244 Antiallergens; autoimmune diseases; antiproliferative agents; controlling signal transduction
12/25/2003US20030236243 Sterically-awkward beta-lactamase inhibitors
12/25/2003US20030236242 Viricides
12/25/2003US20030236240 Macrocycles useful in the treatment of alzheimer's disease
12/25/2003US20030236239 In situ therapy for vision defects; photorefractive therapy
12/25/2003US20030236238 Respiratory system disorders; asthma; stable powder form of formoterol; storage stability
12/25/2003US20030236237 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
12/25/2003US20030236236 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
12/25/2003US20030236235 Method and composition for potentiating the antipyretic action of a nonopioid analgesic
12/25/2003US20030236232 Novel spla2 inhibitors
12/25/2003US20030236230 Comprises 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring; for controlling weight gain in a human or higher mammal
12/25/2003US20030236229 For stimulating the immune system, treating proliferative disorders, or microbial infections
12/25/2003US20030236228 Via administration of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of glutamate, glycine, or both from nerve terminals with the central nervous system
12/25/2003US20030236225 Substituted ethylene diamines for the treatment of infectious diseases; used for mycobacterial infections, including tuberculosis
1 ... 5231 5232 5233 5234 5235 5236 5237 5238 5239 5240 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 ... 7860